secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122337
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics Q3 net loss $32.3M; PRT3789 shows partial responses in SMARCA4-mutated cancers
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $153.6M; net loss $32.3M ($0.43/share) vs $30.6M prior year.
- PRT3789 Phase 1: 4 confirmed partial responses in 26 evaluable SMARCA4-mutated NSCLC/esophageal patients; combo with docetaxel safe.
- Initiated Phase 1 trial of oral SMARCA2 degrader PRT7732 in biomarker-selected SMARCA4-mutated cancers.
- PRT2527 interim Phase 1 data in hematological malignancies to be presented at ASH Dec 2024; dose escalation completing this year.
- Entered collaboration with Pfizer Ignite for SMARCA2 degrader development; Prelude retains full ownership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024122337/0000950170-24-122337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024122337/prld-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer